Download
12254_2023_Article_941.pdf 649,43KB
WeightNameValue
1000 Titel
  • Diagnosis and management of mediastinal extragonadal germ cell tumors
1000 Autor/in
  1. Heidenreich, Axel |
  2. Paffenholz, Pia |
  3. Pfister, David |
1000 Verlag Springer Vienna
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-12-18
1000 Erschienen in
1000 Quellenangabe
  • 17(2):123-129
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12254-023-00941-x |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Summary</jats:title><jats:p>Extragonadal germ cell tumors (EGCT) are rare and comprise only 2–3% of all testicular germ cell tumors. The majority of EGCT are located in the mediastinum, followed by the retroperitoneum. Although histologically similar to germ cell tumors (GCT), EGCT have distinct histological patterns which result in a biologically aggressive variant of GCT with the need for interdisciplinary care in highly specialized centers. The majority of mediastinal EGCT harbor teratoma or yolk sac tumor elements. Treatment usually consists of a combination of systemic cytotoxic therapy and aggressive postchemotherapeutic surgery. First-line treatment for extragonadal seminomas and nonseminomas consists of three and four cycles of PEB or PEI, respectively. In patients with significantly elevated markers, a personalized approach based on adequate marker decline can be used, and in poor-risk patients, first-line high-dose chemotherapy might be discussed. Postchemotherapeutic surgery remains an integral part of the multidisciplinary treatment for nonseminomatous EGCT and it is of utmost importance that all residual masses, independent of size and location, are resected completely. Residual masses in seminomatous EGCTs rarely harbor vital cancer and might be followed by serial imaging studies or FDG-PET/CT. The prognosis of nonseminomatous EGCT is poor, with 5‑year overall survival rates of 17%, 60–70%, and 90% for poor, intermediate, and excellent prognosis, respectively. Prognosis for seminomatous EGCT is excellent, with 5‑year overall survival rates of 95% and 88% for good and intermediate prognosis, respectively. Salvage chemotherapy consists of high-dose chemotherapy or targeted therapy in very selected patients.</jats:p>
1000 Sacherschließung
lokal Malignant somatic transformation
lokal Postchemotherapeutic surgery
lokal Short Review
lokal Testis cancer
lokal Teratoma
lokal Nonseminoma
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2511-3664|https://frl.publisso.de/adhoc/uri/UGFmZmVuaG9seiwgUGlh|https://frl.publisso.de/adhoc/uri/UGZpc3RlciwgRGF2aWQ=
1000 Hinweis
  • DeepGreen-ID: 14f7d8ab81374497b317d151835348c1 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Köln |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Diagnosis and management of mediastinal extragonadal germ cell tumors
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Köln |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6522597.rdf
1000 Erstellt am 2025-07-06T15:48:59.812+0200
1000 Erstellt von 322
1000 beschreibt frl:6522597
1000 Zuletzt bearbeitet 2025-07-31T15:10:08.940+0200
1000 Objekt bearb. Thu Jul 31 15:10:08 CEST 2025
1000 Vgl. frl:6522597
1000 Oai Id
  1. oai:frl.publisso.de:frl:6522597 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source